Regenerex Pharma Files Q3 2024 10-Q

TL;DR

**RGPX files 10-Q for period ending 12/31/24. Pharma company based in Vegas.**

AI Summary

Regenerex Pharma, Inc. filed its quarterly report for the period ending December 31, 2024. The company, formerly known as Peptide Technologies, Inc. and Eternelle Skincare Products Inc., is incorporated in Nevada and operates in the pharmaceutical preparations sector. Its business and mailing address are located at 5348 Vegas Drive, Suite 177, Las Vegas, NV 89108.

Why It Matters

This filing provides an update on Regenerex Pharma's financial and operational status for the third quarter of fiscal year 2024, which is crucial for investors to assess the company's performance and outlook.

Risk Assessment

Risk Level: low — This is a routine quarterly filing providing basic company information and reporting period details, with no immediate red flags.

Key Numbers

• 20241231 — Period End Date (The report covers the financial period ending on this date.)
• 20250207 — Filing Date (The date the 10-Q was officially submitted to the SEC.)

Key Players & Entities

• REGENEREX PHARMA, INC. (company) — Filer
• 20241231 (date) — Period of Report
• 20250207 (date) — Filing Date
• PEPTIDE TECHNOLOGIES, INC. (company) — Former Company Name
• Eternelle Skincare Products Inc. (company) — Former Company Name
• 5348 VEGAS DRIVE, SUITE 177 (address) — Business and Mailing Address
• LAS VEGAS, NV 89108 (address) — Business and Mailing Address

FAQ

Key Financial Figures

• $0.001 — ing at February 07, 2025 Common stock, $0.001 par value 278,465,910 "Explanatory N
• $2,400,000 — million four hundred thousand dollars ($2,400,000) note payable that was due August 17, 2
• $10,000,000 — aised a minimum of ten million dollars ($10,000,000) in sales within the twelve (12) month
• $240,000 — terest-free note payable was issued for $240,000 and is due August 17, 2025. The Compa
• $500 — s are capitalized while purchases under $500 are expensed as incurred. Right of Use
• $262,264 — ounts totaling approximately $ 193,900 ($262,264 Canadian Funds) that came due during th
• $287,018 — mate total principal amount $ 207,400 ($287,018 Canadian Funds) which included the prin
• $24,754 — proximate accrued interest of $ 13,500 ($24,754 Canadian Funds). During the nine-months

Filing Documents

• ixform10q.htm (10-Q) — 452KB
• exhibit31-1.htm (EX-31.1) — 11KB
• exhibit31-2.htm (EX-31.2) — 11KB
• exhibit32-1.htm (EX-32.1) — 4KB
• exhibit32-2.htm (EX-32.2) — 4KB
• regenerexlogo.gif (GRAPHIC) — 6KB
• 0001472375-25-000013.txt ( ) — 2501KB
• rgpx-20241231.xsd (EX-101.SCH) — 24KB
• rgpx-20241231_cal.xml (EX-101.CAL) — 32KB
• rgpx-20241231_def.xml (EX-101.DEF) — 120KB
• rgpx-20241231_lab.xml (EX-101.LAB) — 182KB
• rgpx-20241231_pre.xml (EX-101.PRE) — 157KB
• ixform10q_htm.xml (XML) — 192KB

forward-looking statements are based on a series of expectations, assumptions,

forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. We may not actually achieve the plans, intentions or expectations disclosed in these

forward-looking statements. Actual results or events could differ materially

forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: our ability to add new customers. the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows. the potential benefits of and our ability to maintain our relationships and establish or maintain future collaborations or strategic relationships or obtain additional funding. our marketing capabilities and strategy. our ability to maintain a cost-effective program. our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals. our competitive position, and developments and projections relating to our competitors and our industry. our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and the impact of laws and regulations. All of our forward-looking each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the "SEC") could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to upda

Notes to Financial Statements

Notes to Financial Statements 6 Item 2. Management Discussion & Analysis of Financial Condition and Results of Operations 13 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 18 Item 4.

Controls and Procedures

Controls and Procedures 18 PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 20 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20 Item 3. Defaults Upon Senior Securities 20 Item 4. Mining Safety Disclosures 20 Item 5 Other Information 20 Item 6. Exhibits 20 CERTIFICATIONS 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act 32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 1 PART I FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS REGENEREX PHARMA, INC. BALANCE SHEETS (UNAUDITED) December 31, 2024 March 31, 2024 ASSETS Current Assets Cash and equivalents $ 338 $ 372 Prepaid expenses 650 2,540 Total Current Assets 988 2,912 Website, net of accumulated amortization of $ 30,600 and $ 29,272 , as of December 31 and March 31, 2024,respectively — 1,328 Furniture and computer equipment, net of accumulated depreciation of $ 2,900 and $ 1,600 , as of December 31 and March 31, 2024,respectively 4,797 6,097 Right of use asset 641,075 756,343 Total Assets $ 646,860 $ 766,680 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable $ 184,681 $ 116,760 Related party advances 9,847 3,690 Accrued compensation 802,502 511,847 Other accrued liabilities 141,874 97,251 Current portion of notes payable to shareholder 611,226 475,050 Current portion of notes payable to related parties 408,262 110,500 Current portion of notes payable 2,824,232 2,400,000 Current portion of leases liabilities 177,422 128,264 Total Current Liabilities 5,160,046 3,843,362 Notes payable to shareholder, net of current portion — 119,114 Notes payable, net of current portion — 184,232 Lease liabilities, net of current portion 540,528 681,798 Total Liabilities 5,700,574 4,828,506 Commitments and Contingencies (Note 7) - - Stockholders' Deficit Common stock: $ 0.001 par value; 675,000,000 shares authorized; 278,465,910 and 278,225,910 issued and outstanding as of December 31, 2024 and March 31, 2024, respectively 278,466 278,226 Additional paid-in capital 1,400,326 1,275,798 Accumulated deficit ( 6,732,506 ) ( 5,615,850 ) Total Stockholders' Deficit ( 5,053,714 ) ( 4,061,826 ) Total Liabilities and Stockholders' Deficit $ 646,860 $ 766,680 The accompanying notes are an integral part of these unaudited financial statements. 2 RE

financial statements and the footnotes thereto for the fiscal year ended March

financial statements and the footnotes thereto for the fiscal year ended March 31, 2024, included within the Company's Annual Report on Form 10-K as filed with the Securities and Exchange Commission. 6 NOTE 3 – GOING CONCERN These financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP"), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2024, it had excess liabilities over assets of $ 5,053,714 . These factors raise substantial doubt about the Company's ability to continue as a going concern. The Company requires significant cash to launch its business and reduce its payable. Management's plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or meet financing requirements, management expects that the Company will need to curtail operations, seek additional capital on less favorable terms, and/or pursue other remedial measures. These

financial statements do not include any adjustments related to the

financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company become unable to continue as a going concern. NOTE 4 –SIGNIFICANT ACCOUNTING POLICIES Revenue Recognition The Company will record revenue under ASC 606 by 1) identifying the contract with the customer 2) identifying the performance obligations in the contract 3) determining the transaction price, 4) allocating the transaction price to the required performance obligations in the contract, and 5) recognizing revenue when or as the companies satisfies a performance obligation. We expect to generate revenue from home care service providers that are funded by the U.S. Government, State Medicaid Programs, International Health Care Programs, Veteran's administration, Prison system, Home Health Care Providers, and other applicable Medicare reimbursement models. The Company will defer revenue where the earnings process is not yet complete. To date, no revenue has been generated from the asset acquisition disclosed in Note 1. Earnings per Share Earnings per share is reported in accordance with FASB ASC Topic 260 " Earnings per Share " which requires dual presentation of basic earnings per share ("EPS") and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share.

View Full Filing

View this 10-Q filing on SEC EDGAR